Intravenous Bone Marrow Mononuclear Cells for Acute Ischemic Stroke: Safety, Feasibility, and Effect Size from a Phase I Clinical Trial

Cellular therapy is a promising investigational modality to enhance poststroke recovery. We conducted a single‐arm, phase I clinical trial to determine the safety and feasibility of intravenous (IV) administration of autologous bone marrow mononuclear cells (MNCs) after acute ischemic stroke (AIS)....

Full description

Saved in:

Bibliographic Details
Published in:	Stem cells (Dayton, Ohio) Vol. 37; no. 11; pp. 1481 - 1491
Main Authors:	Vahidy, Farhaan S., Haque, Muhammad E., Rahbar, Mohammad H., Zhu, Hongjian, Rowan, Paul, Aisiku, Imoigele P., Lee, Dean A., Juneja, Harinder S., Alderman, Susan, Barreto, Andrew D., Suarez, Jose I., Bambhroliya, Arvind, Hasan, Khader M., Kassam, Mallikarjuna Rao, Aronowski, Jaroslaw, Gee, Adrian, Cox, Charles S., Grotta, James C., Savitz, Sean I.
Format:	Journal Article
Language:	English
Published:	Hoboken, USA John Wiley & Sons, Inc 01.11.2019 Oxford University Press
Subjects:	Acute brain injury Autografts Bone marrow Bone marrow cells Brain oschemia Clinical trials Confidence intervals Dosage Feasibility Intravenous administration Ischemia Leukocytes (mononuclear) Neurological rehabilitation Regenerative medicine Safety Secondary analysis Stem cells Stroke Stroke Regenerative medicine Neurological rehabilitation Stem cells Acute brain injury Bone marrow cells Brain oschemia
ISSN:	1066-5099, 1549-4918, 1549-4918
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!